NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of Leukemia, a Nature publication. The article, titled “A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1- overexpressing cell lines,” was led by Wilson Miller, M.D., Ph.D., Professor, Medicine and Oncology, McGill University-Jewish General Hospital in Montreal, Canada.
